Most arguments about copper peptides start in the wrong place. The usual question is whether GHK-Cu does anything — and on that, the cell-culture and animal literature is genuinely large. The harder question, and the one that decides whether a serum on your bathroom shelf can work at all, is whether intact GHK-Cu ever reaches the living layers of skin in a meaningful amount. That's the question this post is about: what is GHK-Cu doing at the skin barrier, what the permeation research actually shows, and where GHK-Cu Australia sits legally right now.

The short version: the biology is plausible, the delivery is unresolved, and the measurement methods researchers use to settle it don't agree with each other.

What is GHK-Cu, and why delivery is the whole ballgame

GHK-Cu is glycyl-L-histidyl-L-lysine — a three-amino-acid peptide — complexed with a copper(II) ion. In cosmetics it appears on labels as copper tripeptide-1. The proposed mechanisms (copper-dependent collagen cross-linking, modulation of matrix remodelling, gene-expression effects) are mostly established in cells and in animal wound models, not in adequately powered human trials.

Here's the catch. A 2025 review in BioImpacts dedicated to topically applied GHK lays out the physicochemistry plainly: GHK has a molecular weight of 340.4 Da — comfortably under the ~500 Da rule of thumb for skin permeation — but a calculated logP of about −2.24. That figure matters more than the weight. The stratum corneum is a lipid-rich barrier; a strongly hydrophilic molecule with a logP that far below zero is poorly suited to crossing it. And if some fraction does get through, it then meets skin proteases, which is a second obstacle to intact peptide arriving at its target in useful concentration.

The same review makes an observation that should temper a lot of marketing: despite GHK-Cu and palmitoyl-GHK being among the most widely used anti-wrinkle peptides on the market, the published information on their skin permeability, physicochemical behaviour and effectiveness is, in the authors' assessment, insufficient.

That is not a claim that copper peptide serums do nothing. It's a claim that the evidence chain from "active in a dish" to "active in your dermis" has a gap in the middle, and the gap has not been filled.

GHK-Cu research on permeation: the methods disagree

If delivery is the bottleneck, you'd expect a clean body of permeation data. Instead there's a methods problem.

A January 2025 paper in Molecules asked the question directly in its title — are we even ready to measure skin permeation of GHK-Cu encapsulated in liposomes? Its conclusions are about instrumentation and models as much as about the peptide:

  • Synthetic membranes display significantly poorer barrier properties than real tissue, which tends to flatter a formulation's apparent permeation.
  • Keratinocyte culture models proved unsuitable for estimating transepidermal transport rates; results were not comparable to human skin measurements.
  • Porcine skin preparations gave results closest to human skin, making them the more defensible benchmark.

The practical consequence: two studies can both report that a GHK-Cu formulation "penetrates", using different membranes, and the numbers are not comparable. When you see a penetration percentage quoted in product copy, the model used is the first thing worth asking about — and it's usually not stated.

The fixes under investigation

Formulation science is where the effort is going. Liposomal encapsulation, ionic-liquid carriers, hydrophobic modification (palmitoylation), metal complexation itself, and microneedle pre-treatment have all been proposed to improve GHK delivery. Several show enhanced permeation in laboratory models. None of that is the same as a controlled human trial demonstrating that the enhanced-delivery version produces a better clinical outcome than the ordinary version — that head-to-head work largely hasn't been published.

The definition problem: what's actually in the jar

A broader review published in Pharmaceutics in August 2026 pushes the argument one step further, and it's the most useful framing we've seen this year. Its authors' conclusion is that GHK-Cu translation is limited less by biological plausibility than by pharmaceutical definition and evidence attribution.

In plain terms: "GHK-Cu" is used as though it were one thing, when in practice it covers apo-GHK (the peptide without copper), the canonical 1:1 GHK-copper complex, GHK-derived copper peptides, and unrelated copper-peptide systems. The review proposes a control strategy built on things almost no consumer product discloses — molar copper occupancy, route-specific labile-copper specifications, orthogonal speciation methods, mechanism-linked potency assays and ICH-aligned stability.

Two implications for readers. First, findings attributed to "copper peptide" may have been generated with a different chemical species than the one in a given product. Second, free or loosely bound ("labile") copper is a distinct safety consideration from the intact complex — which is precisely why route matters, and why the injectable conversation is a different risk conversation from the cosmetic one.

One housekeeping note: a recruiting registry listing for a topical GHK-Cu split-wound trial has been circulating. We could not verify the listed sponsor as a real organisation, so we are not treating it as evidence of anything. Registry entries are not peer-reviewed, and we'd suggest checking the sponsor before citing one.

Is GHK-Cu legal in Australia?

Two separate answers, depending on the route.

Topical cosmetic use is legal. Copper tripeptide-1 is used as a cosmetic ingredient in serums and creams sold in Australia, and it's the route with the controlled human cosmetic studies behind it — small, often industry-funded, and focused on skin appearance measures.

Injectable GHK-Cu is unapproved. It is not included in the Australian Register of Therapeutic Goods. The TGA's April 2026 safety alert on unapproved peptide products names GHK-Cu among the compounds being supplied in injectable form, and states these products have not been evaluated for safety, quality or effectiveness. The alert describes reports including severe allergic reactions requiring hospitalisation and liver injury associated with unapproved peptide products generally, and flags that manufacturing origin, sterility and actual contents are frequently unknown.

Note the asymmetry: the route with the most human data is the one you can legally buy, and the route with essentially no published human safety or efficacy data is the one the regulator has warned about. That's the opposite of how a compound usually matures, and it's worth sitting with.

For background on mechanism, dosing claims and the wider literature, see our GHK-Cu profile, or browse the full peptides library. If you'd like new GHK-Cu research and TGA developments summarised as they land, join the free updates list.

What would change our read

  • A permeation study in human or porcine skin, with disclosed method, showing how much intact GHK-Cu reaches the viable epidermis from a commercial-strength formulation.
  • A controlled cosmetic trial comparing an enhanced-delivery GHK-Cu formulation against the same concentration in a conventional base.
  • Products that disclose copper speciation and labile-copper content, so "GHK-Cu" means the same thing across studies.

Until then, the honest position is that the copper peptide's in-vitro biology is well documented, its skin delivery is an open engineering question, and its injectable use in Australia is unapproved and the subject of an active regulatory warning.

FAQ

Does GHK-Cu actually penetrate the skin?

It's unresolved. GHK's molecular weight (340.4 Da) is small enough, but its calculated logP of about −2.24 makes it too hydrophilic to cross the lipid stratum corneum easily, and a 2025 review concluded the published permeability data are insufficient despite widespread cosmetic use.

Is GHK-Cu legal in Australia?

Topical cosmetic use (copper tripeptide-1 in serums and creams) is legal. Injectable GHK-Cu is not on the Australian Register of Therapeutic Goods and is named in the TGA's April 2026 safety alert on unapproved peptide products.

Why do GHK-Cu penetration studies disagree?

Because the test models differ. A 2025 Molecules paper found synthetic membranes have much weaker barrier properties than real tissue and keratinocyte cultures are unsuitable for estimating transepidermal transport, while porcine skin best approximates human skin — so results across studies aren't directly comparable.

Do copper peptide serums work for wrinkles?

There are small controlled cosmetic studies on skin appearance measures, often industry-funded, and the cell-level biology is well documented. What's missing is evidence linking a given product's delivery to its clinical effect, so treat strong efficacy claims cautiously.

Sources

This article is independent information, not medical advice. Topical cosmetic GHK-Cu is legal in Australia; injectable GHK-Cu is unapproved, is not on the ARTG, and is named in the TGA's April 2026 unapproved-peptides alert. Speak with a qualified Australian health practitioner before acting on anything here. retatrutide.net.au is not affiliated with any manufacturer or supplier and does not sell or source peptides.